Case Study: A 38-year-old female diagnosed with adrenal cancer underwent GcMAF therapy as part of her treatment plan. 

 Initially, she presented with symptoms of fatigue, abdominal pain, and hormonal imbalances. 

 Imaging studies revealed a large adrenal mass, and biopsy confirmed the diagnosis of adrenal carcinoma. 

Treatment Plan: The patient received GcMAF injections sub C daily at 2500ng daily, in addition to conventional treatments which were chemotherapy. Over the course of six months, her immune response was closely monitored, and adjustments to the GcMAF dosage were made based on her progress. The patient experienced a significant reduction in tumor size, as evidenced by follow-up imaging studies of 85%. Her overall health improved greatly, with increased energy levels and significant reduced symptoms. 

Outcome:  After one year of combined therapy, the patient showed no signs of cancer recurrence and continued to receive maintenance doses of GcMAF in spray form to support her immune system. This case illustrates the potential incorporating GcMAF into the treatment regime for adrenal cancer, highlighting its role in enhancing the immune response and improving patient outcomes. Author of GcMAF in the treatment of Adrenal cancer. 

Please understand that the above is not meant as medical advice. It is purely for research purposes.